Search News
| 69.20 Delayed Data As of 4:00pm ET |  -0.91 / -1.30%Today’s Change | 60.23 Today|||52-Week Range 140.11 | -26.93% Year-to-Date |
| Rhenman & Partners Asset Management AB Buys Nektar Therapeutics Inc, Walgreens Boots ... 10:40am / GuruFocus News - Paid Partner Content | CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA Jul 19 / Zacks.com - Paid Partner Content |
| Previous close | 70.11 |
| Today’s open | 70.11 |
| Day’s range | 69.02 - 70.11 |
| Volume | 1,040,679 |
| Average volume (3 months) | 2,368,368 |
| Market cap | $14.9B |
| Earnings growth (last year) | -383.33% |
| Earnings growth (this year) | +126.22% |
| Earnings growth (next 5 years) | +63.70% |
| Revenue growth (last year) | +38.93% |
| P/E ratio | NM |
| Price/Sales | 12.61 |
| Price/Book | 9.12 |
| Today’s change | Today’s % change | |
|---|---|---|
| ZTSZoetis Inc | -0.13 | -0.15% |
| ALXNAlexion Pharmaceutic... | +0.07 | +0.05% |
| BAXBaxter International... | +0.26 | +0.35% |
| MYLMylan NV | -0.11 | -0.31% |
| Next reporting date | July 31, 2018 |
| EPS forecast (this quarter) | $0.20 |
| Annual revenue (last year) | $1.5B |
| Annual profit (last year) | -$313.1M |
| Net profit margin | -20.38% |
Sector Health Technology |
Industry Biotechnology |
Chairman, President & Chief Executive Officer Hervé Hoppenot |
Chief Financial Officer & Executive Vice President David W. Gryska |
Corporate headquarters Wilmington, Delaware |
